drugset / Trial / NCT01097304

Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia

NCT01097304

Phase 2 Completed 36 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ursodiol may keep cancer for forming in patients with Barrett esophagus or low-grade dysplasia.

Timeline

Start
2010-04
Primary completion
2014-04
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule Oral